Patent details
92000 Product Name: "Combinaison comprenant de l'aliskiren ou un de ses sels pharmaceutiquement acceptables et de l'amlodipine ou un de ses sels pharmaceutiquement acceptables et de l'hydrochlorothiazide ou un de ses sels pharmaceutiquement acceptables"
Basic Information
- Publication number:
- 92000
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP037300647
- Legal Status:
- Lapsed
- Application number:
- 92000
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
1
- Marketing Authorization Number:
- EU/1/11/730/001-060 - Rasitrio
- Marketing Authorization Type:
- Marketing Authorization Date:
- 22/11/2011
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
2
- Marketing Authorization Number:
- CH-61678 01-05 - Rasilamlo
- Marketing Authorization Type:
- Marketing Authorization Date:
- 05/07/2011
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
Dates
- Filing date:
- 14/05/2012
- First Marketing Authorization date:
- 05/07/2011
- Grant date:
- 16/07/2012
- Activation date:
- Publication date:
- 16/07/2012
- Lapsed date:
- 16/05/2023
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 05/07/2026
- SPC Extension Expiration:
- 05/07/2026
- Rejection date:
- Withdrawal date:
Owner
- From:
- 14/05/2012
- Name:
- Novartis Pharma AG
- Address:
- Lichtstrasse 35, 4056 Basel, Switzerland (CH)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 14/05/2012
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Inventor
1
- Name:
- WEBB Randy, Lee
- Address:
- United States (US)
2
- Name:
- FELDMAN David, Louis
- Address:
- United States (US)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|